美托洛尔加生脉胶囊治疗慢性肾衰竭并慢性心力衰竭疗效观察

Clinical Dbservation of the Curative Effect of Metoprolol and Shengmai Capsule in Treating Chronic Renal Failure and Chronic Heart Failure

目的评价美托洛尔加生脉胶囊治疗慢性肾衰竭(CRF)并慢性心力衰竭(CHF)的临床疗效和安全性。方法52例慢性肾衰竭合并慢性心力衰竭病人随机分为治疗组(27例)与对照组(25例)。随访6个月,分别测量治疗前后心率、血压,采用彩色超声心动图测量心功能进行疗效观察。结果48例患者完成研究,两组治疗后左心室舒张末径,左心室收缩末径(LVEDD)、(LVESD),心功能,症状均有改善,但治疗组比对照组明显,两组比较有显著性差异(P<0.05),两组治疗后血压心率较治疗组明显下降(P<0.01),两组患者治疗后血压无显著性差异(P>0.05)而心率有非常显著性差异(P<0.01)。结论在常规治疗基础上美托洛尔加生脉胶囊能改善慢性肾衰竭并慢性心力衰竭患者的症状及心功能,绝大多数病人可耐受治疗。

Objective To evaluate the efficacy and safety profile of metoprolol and Shengmaimai capsule in chronic renal failure （CRF） and chronic heart failure（CHF）. Methods 52 cases patients with CRF and CHF were divided into treatment group （27 cases） and control group（25 cases）. All the patients were followed up for months and measured respectively the changes of heart rate（HR）, blood puessure（BP） and cardiac function by the colur Dopper ECE. Results 48 patients completed the treatment. The LVEDD, LVESD, heart function and symptoms were improved in both groups while the treatment group was more obvious than the control group （ P 〈0. 05 ）. The result of HR and BP decreased significantly after treatemt comparatively （ P 〈 0. 05 ）, while the HR in the treatment decreased more obvious than the control group （P 〈 0. 01 ）, but there was no significant difference in HR （P 〉 0. 05）. Conclusion On the basis of routine therapy metoyrolol and Shengmaimai capsule can improve the symptoms and heart function significantly in patients with CRF and CHF. Most of patients are able to endure therapy.